Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Wei-Li Min
Antitumor Activity of the Selective Cyclooxygenase-2 Inhibitor, Celecoxib, on Breast Cancer in Vitro and in Vivo
Cancer Cell International
Cancer Research
Oncology
Genetics
Related publications
The Selective Cyclooxygenase-2 Inhibitor Celecoxib Reduces Bone Resorption, but Not Bone Formation, in Ovariectomized Mice in Vivo
Tohoku Journal of Experimental Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Antiangiogenic Activity of the Selective Cyclooxygenase 2 Inhibitor Rofecoxib in Human Colorectal Cancer Liver Metastases
Gut
Gastroenterology
The Protective Effects of Ursodeoxycholic Acid and the Selective Cyclooxygenase-2 Inhibitor Celecoxib on Liver Damage in an Experimental Cholestasis Model
Experimental Biomedical Research
Antitumor Agents. 272. Structure−Activity Relationships and in Vivo Selective Anti-Breast Cancer Activity of Novel Neo-Tanshinlactone Analogues
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Antitumor Activities of JTP-74057 (GSK1120212), a Novel MEK1/2 Inhibitor, on Colorectal Cancer Cell Lines in Vitro and in Vivo
International Journal of Oncology
Cancer Research
Oncology
Cyclooxygenase-2 Inhibitor Celecoxib Attenuates Joint Contracture Following Immobilization in Rat Knees
BMC Musculoskeletal Disorders
Rheumatology
Orthopedics
Sports Medicine
A Tumor-Selective Somatostatin Analog (TT-232) With Strong in Vitro and in Vivo Antitumor Activity.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Changes in Antitumor Response in C57bl/6j-Min/+ Mice During Long-Term Administration of a Selective Cyclooxygenase-2 Inhibitor
Cancer Research
Cancer Research
Oncology
Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Cancer Research
Cancer Research
Oncology
